Registry of patients with multiple sclerosis and COVID-19 infection in Saudi Arabia.

Background: The outbreak of coronavirus disease 2019 (COVID-19) has rapidly spread and developed as a pandemic threatening global health. Patients with multiple sclerosis (MS)-an autoimmune demyelinating inflammatory disease of the central nervous system (CNS)-are predominantly treated with immunomodulatory/immunosuppressive disease-modifying therapies (DMTs), which can increase the risk of infection. Therefore, there is concern that these patients may have a higher risk of COVID-19.

Hypoglycemic and hypolipidemic effects of aqueous extract of phaseolus vulgaris pods in streptozotocin-diabetic rats.

The present investigation was carried out to evaluate the reduction potential of aqueous extract of casing of pods of phaseolus vulgaris in blood glucose and lipids levels among hyperglycemic streptozotocin (STZ)-induced rats. Oral administration of 150mg/kg of aqueous oral administration of aqueous pod extract of phaseolus vulgaris to diabetic rats for 40days resulted in a significant decrease in blood glucose (p<001), cholesterol (P<0.01) and triglycerides (P<0.